Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 4Terminated 2

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Breast 3Head & Neck 2

Conditions

Breast Neoplasms 24Hereditary Sensory and Autonomic Neuropathies 6Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Pre-menopausal Breast Cancer 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Kidney Neoplasms 1Hyperglycemia 1HER2-positive Metastatic Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced or Metastatic ER+ Breast Cancer 1Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1Advanced HER2+Breast Cancer 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × Alpelisib × Clear all
NCT03056755 2026-01-13

BYLieve

Novartis

Phase 2 Completed
383 enrolled 16 charts
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04997902 2025-12-23

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT04899349 2024-10-09

EPIK-B4

Novartis

Phase 2 Terminated
2 enrolled 8 charts
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT03439046 2024-08-01

BioItaLEE

Novartis

Phase 3 Completed
287 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04285723 2023-02-09

EPIK-P1

Novartis

Completed
57 enrolled 23 charts 1 FDA

Hereditary Sensory and Autonomic Neuropathies

NCT01602315 2020-12-29

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Novartis

Phase 1/2 Terminated
179 enrolled 38 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡